FirmaIQ
Org.nr 985 889 635 2019 → 2020 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2020 vs 2019

Weaker earnings, fresh owner capital

approved 2021-06-07; registry 2021-07-12; journal 2021 469791

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2020 with 2019 for LYTIX BIOPHARMA ASA. Revenue 6.70m NOK → 6.68m NOK (-0.3%). Net result -33.23m NOK → -42.09m NOK. Equity 14.39m NOK → 19.89m NOK.

On the constructive side: equity strengthened; cash rose; owners injected capital. Pressures included: revenue fell; operating result weakened; net result weakened.

Mixed year — gains and pressures both show up.

At a glance

Scorecard

Revenue
6.70m NOK 6.68m NOK
-0.3%
Operating result
-33.77m NOK -42.37m NOK
-25.5%
Net result
-33.23m NOK -42.09m NOK
-26.7%
Equity
14.39m NOK 19.89m NOK
+38.2%
Cash
12.80m NOK 28.45m NOK
+122.3%
Total assets
17.43m NOK 32.62m NOK
+87.1%

What improved

  • ↑

    Equity strengthened

    Book equity 14.39m NOK → 19.89m NOK (equity ratio 82.6% → 61.0%). Calculated

  • ↑

    Cash rose

    Bank deposits 12.80m NOK → 28.45m NOK (+122.3% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 14.39m NOK → 19.89m NOK (+5.50m NOK). Reported fact

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 6.70m NOK to 6.68m NOK (-0.3% YoY). Calculated

  • ↓

    Operating result weakened

    Operating result -33.77m NOK → -42.37m NOK (op. margin -504.2% → -634.5%). Calculated

  • ↓

    Net result weakened

    Net result -33.23m NOK → -42.09m NOK (net margin -496.1% → -630.2%). Calculated